<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6893791\results\search\disease\results.xml">
  <result pre="diseases. Recent decline in vaccination coverage resulted in re-emergence of" exact="measles" post="outbreaks. Measles virus (MeV) infection causes an acute systemic"/>
  <result pre="disease. Early following MeV infection some patients develop acute post-infectious" exact="measles" post="encephalitis (APME), which is not associated with direct infection"/>
  <result pre="Early following MeV infection some patients develop acute post-infectious measles" exact="encephalitis" post="(APME), which is not associated with direct infection of"/>
  <result pre="and cause sub-acute sclerosing panencephalitis (SSPE) in immunocompetent people or" exact="measles" post="inclusion-body encephalitis (MIBE) in immunocompromised patients. To date, cellular"/>
  <result pre="sub-acute sclerosing panencephalitis (SSPE) in immunocompetent people or measles inclusion-body" exact="encephalitis" post="(MIBE) in immunocompromised patients. To date, cellular and molecular"/>
  <result pre="advanced therapeutic approaches potentially applicable to treat MeV CNS infection." exact="measles" post="virus central nervous system tropism treatments 1. Measles Virus"/>
  <result pre="Epidemiology Measles virus (MeV) is the etiologic agent responsible for" exact="measles" post="disease. Humans are the only known reservoir for MeV."/>
  <result pre="MeV. Despite the availability of a very efficient vaccine [1]," exact="measles" post="remains one of the most contagious diseases with a"/>
  <result pre="After decades of emergences mainly restricted to the poorest countries," exact="measles" post="has made a strong comeback and re-emerged in industrialized"/>
  <result pre="there are 7 to 20 million people getting infected by" exact="measles" post="each year [7,8]. In most developed countries measles was"/>
  <result pre="infected by measles each year [7,8]. In most developed countries" exact="measles" post="was considered eliminated, in recent years. However the rate"/>
  <result pre="the decreased herd immunity led to large outbreaks and today" exact="measles" post="is considered re-emerged [4,9]. This year, in many developed"/>
  <result pre="[24], and through a nectin-4-mediated macropinocytosis pathway, in breast and" exact="colon cancer" post="cell lines (MCF7, HTB-20, and DLD-1) [25]. It was"/>
  <result pre="and through a nectin-4-mediated macropinocytosis pathway, in breast and colon" exact="cancer" post="cell lines (MCF7, HTB-20, and DLD-1) [25]. It was"/>
  <result pre="A highly efficient live-attenuated virus vaccine is available to prevent" exact="measles" post="outbreaks. MeV transmissibility is very high and 95% of"/>
  <result pre="the Centers for Disease Control (CDC), the experts agreed that" exact="measles" post="eradication was technically feasible by 2005â€“2010. Nevertheless, vaccination coverage"/>
  <result pre="Nevertheless, vaccination coverage decreased and led to a re-emergence of" exact="measles" post="infection. Nowadays, measles global eradication is one of the"/>
  <result pre="decreased and led to a re-emergence of measles infection. Nowadays," exact="measles" post="global eradication is one of the top priorities of"/>
  <result pre="the WHO. The Global Vaccine Action Plan aims to eliminate" exact="measles" post="in five WHO Regions by 2020. Based on confirmed"/>
  <result pre="cases reported by the WHO, the countries with the most" exact="measles" post="cases in 2018 were India, Ukraine, Philippines, Brazil, and"/>
  <result pre="in 2018 were India, Ukraine, Philippines, Brazil, and Yemen. Recently," exact="measles" post="strongly re-emerged in industrialized countries due to the significant"/>
  <result pre="Tanabe (Japan, 1968) strain. All vaccines strains belong to the" exact="measles" post="virus genotype A [45]. Measles vaccine is usually combined"/>
  <result pre="virus genotype A [45]. Measles vaccine is usually combined with" exact="mumps" post="and rubella vaccines, known as MMR (Measles, Mumps, and"/>
  <result pre="A [45]. Measles vaccine is usually combined with mumps and" exact="rubella" post="vaccines, known as MMR (Measles, Mumps, and Rubella) vaccine,"/>
  <result pre="(Measles, Mumps, Rubella, and Varicella) vaccine. MMR is a live-attenuated" exact="measles" post="virus [46]. MMR vaccination is given in a two-dose"/>
  <result pre="who received the two vaccine doses do not produce protective" exact="measles" post="antibodies. However, most of them remain protected by their"/>
  <result pre="regulatory cells homeostasis by increasing their frequency and attenuating the" exact="hypersensitivity" post="cellular response [55]. A more recent study suggests a"/>
  <result pre="response [55]. A more recent study suggests a MeV-induced immune" exact="amnesia" post="relying on the depletion of pre-existing memory lymphocytes [50]."/>
  <result pre="complications such as pneumonia, which is the main cause of" exact="measles" post="mortality [56] or to central nervous system (CNS) complications,"/>
  <result pre="such as malnutrition and vitamin A deficiency seem to increase" exact="measles" post="associated morbidity and mortality. Indeed, regardless of vaccination coverage,"/>
  <result pre="vaccination, hearing loss was observed in 5% to 10% of" exact="measles" post="cases in the USA. This remains highly frequent in"/>
  <result pre="low [70]. One possible explanation is that otitis associated with" exact="measles" post="in up to 25% of infected patients could cause"/>
  <result pre="after the acute phase of the infection or later following" exact="measles" post="acute encephalitis (described in paragraph 6.1) with typical bilateral"/>
  <result pre="acute phase of the infection or later following measles acute" exact="encephalitis" post="(described in paragraph 6.1) with typical bilateral and moderate"/>
  <result pre="in paragraph 6.1) with typical bilateral and moderate to profound" exact="sensorineural hearing loss" post="[69]. The mechanism associated with MeV-induced hearing loss remains"/>
  <result pre="inner ear [57]. 5.2. Blindness Eye related symptoms such as" exact="conjunctivitis" post="or corneal inflammation (keratitis) are commonly associated with measles"/>
  <result pre="as conjunctivitis or corneal inflammation (keratitis) are commonly associated with" exact="measles" post="[57]. Corneal complications are often more serious when superinfection"/>
  <result pre="measles-induced blindness. Indeed, vitamin A deficiency is associated with severe" exact="keratitis" post="and considerably increases the risk of xerophthalmia, corneal ulceration,"/>
  <result pre="xerophthalmia, corneal ulceration, and blindness [72]. This may explain why" exact="measles" post="related blindness is more common in areas where children"/>
  <result pre="latter being subdivided in two sub-types, the first as a" exact="measles" post="inclusion-body encephalitis (MIBE) in immunocompromised patients and the second"/>
  <result pre="subdivided in two sub-types, the first as a measles inclusion-body" exact="encephalitis" post="(MIBE) in immunocompromised patients and the second as a"/>
  <result pre="encephalitis (MIBE) in immunocompromised patients and the second as a" exact="subacute sclerosing panencephalitis" post="(SSPE) occurring in immunocompetent patients [79,80] (Figure 2B). 6.1."/>
  <result pre="patients [79,80] (Figure 2B). 6.1. Acute Encephalitis The acute post-infectious" exact="measles" post="encephalitis (APME) occurs in 0.1% of measles cases, about"/>
  <result pre="[79,80] (Figure 2B). 6.1. Acute Encephalitis The acute post-infectious measles" exact="encephalitis" post="(APME) occurs in 0.1% of measles cases, about a"/>
  <result pre="The acute post-infectious measles encephalitis (APME) occurs in 0.1% of" exact="measles" post="cases, about a week following the appearance of first"/>
  <result pre="of first clinical signs. The APME is also called post-infection" exact="encephalitis" post="(PIE), acute demyelinating encephalomyelitis, or acute disseminated encephalomyelitis. APME"/>
  <result pre="is also called post-infection encephalitis (PIE), acute demyelinating encephalomyelitis, or" exact="acute disseminated encephalomyelitis." post="APME is associated with 20% mortality and severe neurological"/>
  <result pre="contribute to this inflammatory immune reaction [88]. Overall, MeV acute" exact="encephalitis" post="is poorly described in the recent literature. Note that"/>
  <result pre="detection in certain cases, multiple groups have suggested that the" exact="encephalitis" post="could be caused by an autoimmune-like response [89]. While"/>
  <result pre="11 cases per 100,000 [97,98] in immunocompetent patients that contracted" exact="measles" post="in their childhood, with a mortality rate close to"/>
  <result pre="and S103I/N462S/N465S) also confer hyperfusogenicity and can spread in human" exact="neuroblastoma" post="cell lines and suckling hamster brains in the absence"/>
  <result pre="block [29,96,145,146] (Table 1). Non-human primates represent faithful models of" exact="measles" post="since they are fully susceptible to wild-type MeV infection"/>
  <result pre="the acute pathogenesis [20,65,66,68,148,149,150]. These studies highlighted numerous similarities between" exact="measles" post="pathogenesis in humans and primates. Particularly, they allowed confirming"/>
  <result pre="in one monkey and two monkeys showed neuronal inclusions with" exact="measles" post="antigens [152] but no infectious viral particle has been"/>
  <result pre="reported that rhesus monkeys infected intracerebrally with hamster-brain-adapted strain developed" exact="encephalitis" post="with morphological characteristics similar to those observed in the"/>
  <result pre="Additionally, other hyperfusogenic mutants more stable and also observed in" exact="encephalitis" post="cases were shown to conserve there dependence on H"/>
  <result pre="immunocompetent OBC. Astrogliosis and microgliosis have been observed in MeV" exact="encephalitis" post="[144,187,188]. These data could explain why infection of astrocytes"/>
  <result pre="Dissemination? Neuronal cell lines such as human cells NT2, human" exact="astrocytoma" post="cells, or mouse neuroblastoma cells were also used, but"/>
  <result pre="such as human cells NT2, human astrocytoma cells, or mouse" exact="neuroblastoma" post="cells were also used, but their relevance remains difficult"/>
  <result pre="to 79% protection to unvaccinated patients having close contact with" exact="measles" post="infected patients [200]. More recently, effectiveness of immune serum"/>
  <result pre="prophylaxis was estimated from 50% to 69% during the 2014" exact="measles" post="outbreak in British Columbia in Canada. However, this estimation"/>
  <result pre="the vaccine compared to the acquisition from a wild type" exact="measles" post="infection [202]. This led to the necessity to increase"/>
  <result pre="serum globulin in order to maintain a protective level of" exact="measles" post="antibodies [201]. However, as mentioned in paragraph 7.3, SSPE"/>
  <result pre="via intracerebral route led to persistency of MeV infection and" exact="encephalitis" post="[204,205,206]. Thus, the use of immunoglobulins to treat measles"/>
  <result pre="and encephalitis [204,205,206]. Thus, the use of immunoglobulins to treat" exact="measles" post="infection should be very carefully thought before introduction in"/>
  <result pre="effectiveness [210]. Many clinical reports show that Ribavirin can decrease" exact="measles" post="antibody titers in cerebrospinal fluid (CSF) of SSPE patients"/>
  <result pre="11.2.3. Vitamin A Vitamin A deficiency is highly related to" exact="measles" post="complications and the supplementation of vitamin A has been"/>
  <result pre="may not act as a therapeutic cure and prevent from" exact="encephalitis" post="in this particular case [237]. 11.3. Transcription/Replication Inhibitors In"/>
  <result pre="emergence of escape mutant virus [244]. While already used in" exact="cancer" post="treatment, antivirals directly targeting the chaperon activity of HSP90"/>
  <result pre="there is a high probability that Remdesivir may also inhibit" exact="measles" post="virus polymerase activity. Interestingly, pharmakokinetic studies performed in non-human"/>
  <result pre="of MeV studies, especially because of the recent re-emergences of" exact="measles" post="and the increasing number of associated fatal encephalitis [44,256]."/>
  <result pre="re-emergences of measles and the increasing number of associated fatal" exact="encephalitis" post="[44,256]. While the vaccine remains the most efficient prevention"/>
  <result pre="further propagation in the brain. Regardless of the type of" exact="encephalitis" post="or MeV variant invading the brain, the high mortality"/>
  <result pre="variant invading the brain, the high mortality rate associated to" exact="measles" post="virus CNS complication highlight the requirement to validate antiviral"/>
  <result pre="the cytoplasm. Figure 2 Course of MeV infection leading to" exact="measles" post="encephalitis. (A) Initially, MeV infects myeloid cells in the"/>
  <result pre="of transient immunosuppression or autoimmunity, patients can develop acute post-infectious" exact="measles" post="encephalitis (APME) shortly after exposure without systematic central nervous"/>
  <result pre="transient immunosuppression or autoimmunity, patients can develop acute post-infectious measles" exact="encephalitis" post="(APME) shortly after exposure without systematic central nervous system"/>
  <result pre="after exposure without systematic central nervous system (CNS) infection. However," exact="measles" post="inclusion-body encephalitis (MIBE) and subacute sclerosing panencephalitis (SSPE) are"/>
  <result pre="without systematic central nervous system (CNS) infection. However, measles inclusion-body" exact="encephalitis" post="(MIBE) and subacute sclerosing panencephalitis (SSPE) are associated with"/>
  <result pre="nervous system (CNS) infection. However, measles inclusion-body encephalitis (MIBE) and" exact="subacute sclerosing panencephalitis" post="(SSPE) are associated with MeV infection of the CNS."/>
  <result pre="MeV infection of the CNS. (B) The occurrence of MeV" exact="encephalitis" post="may range from one day to 15 years following"/>
  <result pre="Innate immune response i.p.i.n. CD46 IFN-Î±/Î²KO [163] Induction of MeV" exact="encephalitis" post="with Edmonston i.c. CD46 RagKO [96,103] Study of the"/>
  <result pre="rat (Sigmodon hispidus) [12,172,173] Treatment development.Respiratory infectionMeV induced immunosuppressionCNS infectionImmune" exact="suppression" post="i.n. CD46 Sprague-Dawley rat [174] permissiveness Multiple Brown Norway"/>
 </snippets>
</snippetsTree>
